MX365711B - Administración efectiva de genes grandes por vectores aav duales. - Google Patents

Administración efectiva de genes grandes por vectores aav duales.

Info

Publication number
MX365711B
MX365711B MX2015014423A MX2015014423A MX365711B MX 365711 B MX365711 B MX 365711B MX 2015014423 A MX2015014423 A MX 2015014423A MX 2015014423 A MX2015014423 A MX 2015014423A MX 365711 B MX365711 B MX 365711B
Authority
MX
Mexico
Prior art keywords
aav vectors
effective delivery
dual aav
large genes
genes
Prior art date
Application number
MX2015014423A
Other languages
English (en)
Other versions
MX2015014423A (es
Inventor
Alberto Auricchio
Pasqualina Colella
Ivana Trapani
Original Assignee
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Telethon filed Critical Fond Telethon
Publication of MX2015014423A publication Critical patent/MX2015014423A/es
Publication of MX365711B publication Critical patent/MX365711B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a construcciones, vectores, células hospederas y composiciones farmacéuticas relativas que permiten una terapia genética eficaz, en particular de genes más grandes de 5kb.
MX2015014423A 2013-04-18 2014-04-18 Administración efectiva de genes grandes por vectores aav duales. MX365711B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361813342P 2013-04-18 2013-04-18
PCT/EP2014/058000 WO2014170480A1 (en) 2013-04-18 2014-04-18 Effective delivery of large genes by dual aav vectors

Publications (2)

Publication Number Publication Date
MX2015014423A MX2015014423A (es) 2016-07-28
MX365711B true MX365711B (es) 2019-06-11

Family

ID=50678160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014423A MX365711B (es) 2013-04-18 2014-04-18 Administración efectiva de genes grandes por vectores aav duales.

Country Status (11)

Country Link
US (1) US10494645B2 (es)
EP (1) EP2986635B1 (es)
JP (1) JP6453307B2 (es)
CN (1) CN105408352B (es)
AU (1) AU2014255665B2 (es)
CA (1) CA2909733C (es)
DK (1) DK2986635T3 (es)
EA (1) EA034575B1 (es)
ES (1) ES2704677T3 (es)
MX (1) MX365711B (es)
WO (1) WO2014170480A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
EP4410805A2 (en) 2014-03-18 2024-08-07 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3209311B1 (en) 2014-10-21 2024-03-06 University of Massachusetts Recombinant aav variants and uses thereof
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
RU2749882C2 (ru) 2014-11-14 2021-06-18 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
RS63416B1 (sr) * 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
CA3021949C (en) 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
US20180161405A1 (en) 2015-06-04 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved methods for treating ocular diseases by gene therapy
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
US11253576B2 (en) 2015-10-22 2022-02-22 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
AU2016355343C1 (en) 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
BR112018011838A2 (pt) * 2015-12-14 2018-12-04 The Trustees Of The University Of Pennsylvania terapia gênica para distúrbios oculares
WO2017108931A1 (en) * 2015-12-22 2017-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
EP3440210A4 (en) 2016-04-05 2019-11-27 University of Massachusetts COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
KR20190020745A (ko) * 2016-06-15 2019-03-04 옥스포드 유니버시티 이노베이션 리미티드 Abc4a를 발현시키기 위한 이중 중첩 아데노-관련 바이러스 벡터 시스템
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
MA47820A (fr) 2017-03-10 2020-01-15 Genethon Traitement de la glycogénose de type iii
AU2018248304C1 (en) * 2017-04-05 2023-02-16 University Of Massachusetts Minigene therapy
WO2018195555A1 (en) * 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
KR20230167138A (ko) * 2017-05-05 2023-12-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 오토펄린을 발현시키기 위한 조성물 및 방법
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US11859179B2 (en) 2017-05-09 2024-01-02 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (ALS)
US11827898B2 (en) 2017-06-14 2023-11-28 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018338188A1 (en) 2017-09-22 2020-04-02 University Of Massachusetts SOD1 dual expression vectors and uses thereof
CN111386348B (zh) * 2017-10-11 2023-08-22 赛特瑞恩股份有限公司 用于制备高表达和高性能靶蛋白的表达盒及其用途
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EA202091995A1 (ru) * 2018-02-22 2021-03-30 Акуос, Инк. Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека
WO2019195726A1 (en) 2018-04-05 2019-10-10 Oxford University Innovation Limited Compositions and methods for the treatment of stargardt disease
EP3781213A4 (en) * 2018-04-17 2022-10-19 The Trustees of the University of Pennsylvania TRANS-SPLICE MOLECULES
US11660353B2 (en) * 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
US20210277417A1 (en) * 2018-06-25 2021-09-09 Akouos, Inc. Methods of treating clrn1-associated hearing loss and/or vision loss
US20210330814A1 (en) * 2018-07-13 2021-10-28 Akouos, Inc. Methods of treating non-syndromic sensorineural hearing loss
CN109136266B (zh) * 2018-08-10 2022-02-18 深圳泓熙生物科技发展有限公司 用于治疗或预防结晶样视网膜色素变性的基因载体及其用途
AU2019360372A1 (en) * 2018-10-15 2021-06-03 Fondazione Telethon Intein proteins and uses thereof
US20210395778A1 (en) * 2018-11-01 2021-12-23 University Of Florida Research Foundation, Incorporated A codon optimized otoferlin aav dual vector gene therapy
EP3880826A4 (en) * 2018-11-07 2022-08-24 Akouos, Inc. USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/EXPRESS PROTEINS IN CILIATE AND SUPPORTING CELLS IN THE INNER EAR
CN113874512A (zh) * 2018-11-07 2021-12-31 阿库斯股份有限公司 诱导毛细胞分化的组合物和方法
US20220160898A1 (en) * 2018-12-10 2022-05-26 Vigeneron Gmbh An optimized acceptor splice site module for biological and biotechnological applications
WO2020214990A1 (en) * 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Abca4 cell line and methods of use
WO2020214796A1 (en) * 2019-04-19 2020-10-22 University Of Massachusetts Gene therapies for usher syndrome (ush2a)
WO2020214797A1 (en) * 2019-04-19 2020-10-22 University Of Massachusetts Gene therapies for usher syndrome (ush1b)
EP3972610A4 (en) * 2019-05-20 2024-01-17 University of Massachusetts MINI-GENE THERAPY
JP2022538598A (ja) * 2019-06-25 2022-09-05 ミガル ガリラヤ リサーチ インスティテュート リミテッド プレｍＲＮＡのトランススプライシングに基づく合成転写用論理「ＡＮＤ」ゲートを作製するためのシステムおよびその使用
US20220267802A1 (en) * 2019-07-15 2022-08-25 President And Fellows Of Harvard College Methods and compositions for gene delivery
CN113122657B (zh) * 2019-12-31 2022-07-29 上海吉凯基因医学科技股份有限公司 一种多重aav病毒滴度的检测方法
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
AU2021247172A1 (en) * 2020-04-01 2022-09-15 University Of Florida Research Foundation, Incorporated Dual AAV-MY07A vectors with improved safety for the treatment of USH1B
CA3175197A1 (en) * 2020-04-29 2021-11-04 Joseph J. HIGGINS Compositions and methods for treatment of inherited macular degeneration
US20230287458A1 (en) * 2020-07-14 2023-09-14 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery
CN111926085B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种影响鸡肌肉亮度的分子标记及其应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022174146A1 (en) * 2021-02-12 2022-08-18 Greffex, Inc. Gene therapy for retinal diseases
US11603541B2 (en) * 2021-05-06 2023-03-14 Kinase Pharma Inc. Compositions and method of making a complex able to increase production of a cetuximab-like protein (CLP) in a target cell
CN117377771A (zh) * 2021-05-12 2024-01-09 特莱索恩基金会 载体系统
CN115074369B (zh) * 2022-06-24 2023-10-20 成都金唯科生物科技有限公司 表达全长abca4基因的腺相关病毒载体及应用
CN118345117A (zh) * 2023-01-16 2024-07-16 苏州吉恒基因科技有限公司 重组腺相关病毒大基因包装表达载体的构建生产和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356130A3 (en) * 1988-08-22 1991-09-11 Genencor International, Inc. A mobile fl phage single-strand dna origin of replication
US6255071B1 (en) * 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
GB9720465D0 (en) * 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6846970B1 (en) * 1999-07-19 2005-01-25 Plant Bioscience Limited Transformation method and transgenic plants produced thereby
US7250406B2 (en) * 2002-04-19 2007-07-31 Georgia Tech Research Corporation Compositions and methods for the acceleration of protein secretion dynamics
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
WO2008106644A2 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
WO2013075008A1 (en) * 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy

Also Published As

Publication number Publication date
CA2909733C (en) 2023-10-17
EP2986635A1 (en) 2016-02-24
EA201591992A1 (ru) 2016-04-29
BR112015026422A2 (pt) 2017-11-14
AU2014255665B2 (en) 2018-08-02
US20160076054A1 (en) 2016-03-17
CN105408352B (zh) 2020-01-14
CN105408352A (zh) 2016-03-16
DK2986635T3 (en) 2019-01-28
US10494645B2 (en) 2019-12-03
ES2704677T3 (es) 2019-03-19
AU2014255665A1 (en) 2015-11-12
WO2014170480A1 (en) 2014-10-23
JP2016516424A (ja) 2016-06-09
EA034575B1 (ru) 2020-02-21
EP2986635B1 (en) 2018-10-03
CA2909733A1 (en) 2014-10-23
MX2015014423A (es) 2016-07-28
JP6453307B2 (ja) 2019-01-16

Similar Documents

Publication Publication Date Title
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
MX2023004479A (es) Sistema de vector multiple y sus usos.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
IN2014DN08812A (es)
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
HK1206782A1 (en) Widespread gene delivery of gene therapy vectors
MX2021009118A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
WO2012112578A3 (en) Improved aav8 vector with enhanced functional activity and methods of use thereof
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
MX2015014851A (es) Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer.
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2021004391A (es) Proteinas inteinas y usos de las mismas.
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
EP2987504A4 (en) NON-VIRAL GENE DELIVERY SYSTEM FOR TARGETING ADIPOSE CELLS
WO2014195356A3 (en) Alpha-amylase variants and polynucleotides encoding same
IN2014CN03187A (es)

Legal Events

Date Code Title Description
FG Grant or registration